The question becomes even more pressing when your compound is biosimilar. To ensure analytical similarity, you need to measure and control your constants and variables.

icIEF technology and reagents are required for its ability to reveal key critical quality attributes, and a deep understanding of the icIEF profile – including the content of each peak – is crucial for biosimilars developers.

icIEF is a gold-standard method for assessing the critical quality attribute of charge heterogeneity in protein-based biotherapeutics. Surprises in the charge heterogeneity profile are unpleasant but do occur. But what do you DO to determine the identity of each of the biotherapeutic protein's icIEF peaks?

icIEF has been challenging before, but with patented AES technology solutions focused on fractionation, you can – in days, rather than months – collect enough quantity – in high enough purity to perform deep profiling of each peak.

using high-yield icIEF fractionation, which provides sufficient material within days for deep profiling of your compound – for each icIEF peak: peptide mapping, subunit analysis, or activity-based ligand-binding assays such as surface plasmon resonance (SPR).

icIEF-MS coupling to your favourite mass spectrometer is achievable for simply checking the identity of the peaks.